FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.
Key Details
- 1FDA rejected Harrison.ai's petition seeking 510(k) exemption for four types of radiology AI (CADx, CADe, CADt, CADe/x) under specific classifications.
- 2At least 255 radiology AI devices received 510(k) clearance in 2025 alone, per FDA records.
- 3FDA clarified prior clearance does not guarantee manufacturer competence for future device development.
- 4Manufacturer-proposed self-evaluation and risk plans were dismissed due to insufficient FDA oversight mechanisms.
- 5Most public comments opposed the exemption, and FDA detailed significant differences between CADe, CADx, and CADe/x devices impacting regulatory needs.
- 6The agency emphasized vulnerabilities in relying on end-users (radiologists) to catch all performance issues.
Why It Matters
This decision underscores the FDA’s commitment to robust regulatory oversight for radiology AI, potentially affecting product development timelines and market strategies. The nuanced treatment of different device categories and the rejection of broad user detection arguments highlight stringent evidentiary requirements that developers must meet.
Source
AuntMinnie
Related News
•Radiology Business
Majority of Patients Want Disclosure When AI Used in Imaging
A new survey finds that nearly all patients want to be informed when AI is utilized in medical imaging interpretation.
•Cardiovascular Business
Radiology Maintains Lead in FDA-Cleared AI Algorithms, Cardiology Follows
Radiology remains the top specialty for FDA-cleared AI, with cardiology as a strong second, particularly in cardiovascular imaging.
•Radiology Business
Radiology AI Devices at Elevated Risk for FDA Recalls, Study Finds
Radiology AI devices are more likely to face FDA recalls, largely due to deviations from intended use and incomplete clinical data.